Mirna Therapeutics, Inc. (NASDAQ:MIRN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May19, 2017, Vincent ONeill, M.D., Chief Medical Officer of
Mirna Therapeutics, Inc. (Mirna or the Company), and the Company
mutually agreed that Dr.ONeill would resign as Chief Medical
Officer of the Company, effective as of May19, 2017 (the
Separation Date).
In connection with Dr.ONeills departure from the Company and in
consideration of his release of claims against the Company, the
Company entered into a Separation Agreement, effective May26,
2017 (the Agreement), with Dr.ONeill. Under the Agreement,
Dr.ONeill ceased serving as an employee of the Company effective
as of the Separation Date. Dr.ONeill will be entitled to (i)a
severance payment equal to $459,000, which represents twelve
months of Dr.ONeills base salary in effect as of immediately
prior to the Separation Date and one times his target annual
bonus assuming achievement of his performance goals at target,
(ii)payment of his COBRA premiums for up to twelve months
following the Separation Date, and (iii)50% vesting acceleration
on his outstanding equity awards as of the Separation Date.
The foregoing description of the material terms of the Agreement
is not complete and is qualified in its entirety by reference to
the full text of the Agreement, which is filed as an exhibit
hereto.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 |
Separation Agreement, effective as of May26, 2017, by and between the Company and Vincent ONeill. |
About Mirna Therapeutics, Inc. (NASDAQ:MIRN)
Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7. Mirna Therapeutics, Inc. (NASDAQ:MIRN) Recent Trading Information
Mirna Therapeutics, Inc. (NASDAQ:MIRN) closed its last trading session up +0.02 at 1.46 with 128,239 shares trading hands.
